KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Common Equity (2016 - 2026)

Quest Diagnostics' Common Equity history spans 18 years, with the latest figure at $7.4 billion for Q1 2026.

  • On a quarterly basis, Common Equity rose 5.8% to $7.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $7.4 billion, a 5.8% increase, with the full-year FY2025 number at $7.2 billion, up 5.24% from a year prior.
  • Common Equity hit $7.4 billion in Q1 2026 for Quest Diagnostics, up from $7.2 billion in the prior quarter.
  • Over the last five years, Common Equity for DGX hit a ceiling of $7.4 billion in Q1 2026 and a floor of $5.9 billion in Q4 2022.
  • Historically, Common Equity has averaged $6.6 billion across 5 years, with a median of $6.5 billion in 2024.
  • Biggest five-year swings in Common Equity: decreased 8.53% in 2022 and later increased 9.15% in 2025.
  • Tracing DGX's Common Equity over 5 years: stood at $5.9 billion in 2022, then increased by 6.95% to $6.3 billion in 2023, then increased by 7.43% to $6.8 billion in 2024, then increased by 5.24% to $7.2 billion in 2025, then rose by 2.73% to $7.4 billion in 2026.
  • Business Quant data shows Common Equity for DGX at $7.4 billion in Q1 2026, $7.2 billion in Q4 2025, and $7.3 billion in Q3 2025.